차세대 유방암 진단 및 검사 시장 - 세계 시장 및 지역별 분석 : 기술별, 암 아형별, 바이오마커별, 제공별, 최종사용자별, 국가별 분석 : 분석 및 예측(2023-2032년)

“The global next-generation breast cancer diagnostic and screening market is estimated to reach $9,880.1 million in 2032, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 12.57% during the forecast period 2023-2032.”

The next-generation breast cancer diagnostic and screening market will witness significant growth in the forecast period 2023-2032, owing to an increase in the prevalence of breast cancer globally, and the trend is anticipated to continue over the coming years.

USP of the Report

• Overview of the overall oncology molecular diagnostics market
• Key trends and opportunities of the market
• Regulatory framework and list of regulatory-approved products
• Breast cancer clinical trials
• Advantages and limitations of different techniques
• Product pricing
• Impact of COVID-19 on the market
• Market dynamics, including drivers and restraints
• Opportunity mapping by each segment and by companies
• Region and country-level analysis, including market dynamics and market size and forecast
• Market share analysis of key players in the market

Analyst Perspective

According to Satyendrsingh Rajput, Lead Research Analyst, BIS Research, "The increasing burden of breast cancer is leading to a rise in demand for early and effective diagnosis and screening of the disease, which is leading to the adoption of genomic and molecular-based tests that can provide information to healthcare professionals regarding genetic mutations, tumor grade, and presence of hormone receptors, among others. With the development of these diagnostic techniques, the clinical practice for the treatment of cancer is moving toward a more holistic approach of providing prognostic value and personalized therapeutics for the treatment. This inclination toward a personalized approach is paving the way for the growth of the next-generation breast cancer diagnostic and screening market."

Key Companies Operating in The Market

Key players in the global next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.

The key players profiled in the report include Abbott Laboratories, Agendia Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BGI Genomics Co., Ltd., CENTOGENE N.V., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., Lucence Diagnostics Pte Ltd, Myriad Genetics, Inc., and Natera, Inc.

Key Questions Answered in the Report

• What are the major market drivers, challenges, and opportunities in the global next-generation breast cancer diagnostic and screening market?
• What are the emerging trends within the global next-generation breast cancer diagnostic and screening market?
• How is each segment of the next-generation breast cancer diagnostic and screening market expected to grow during the forecast period, and what is the anticipated revenue generated by each of the segments by the end of 2032?
• What are the significant developmental strategies implemented by the major players to sustain in the competitive market?
• Who are the leading players with significant offerings to the next-generation breast cancer diagnostic and screening market? What is the current market dominance for each of these leading players?
• What is the regulatory framework in the global next-generation breast cancer diagnostic and screening market?
• What is the growth potential of the global next-generation breast cancer diagnostic and screening market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
• What was the impact of COVID-19 on global next-generation breast cancer diagnostic and screening?

Industry Overview

The global next-generation breast cancer diagnostic and screening market was valued at $3,137.4 million in 2022 and is anticipated to reach $9,880.1 million by 2032, witnessing a CAGR of 12.57% during the forecast period 2023-2032. The growth in the global next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases globally, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.

Market Lifecycle Stage

The next-generation breast cancer diagnostic and screening market is in the developing phase. Technological advancements in the development of next-generation breast cancer diagnostics and the growing scope for molecular breast cancer diagnosis techniques in emerging countries can be some of the major opportunities in the global next-generation breast cancer diagnostic and screening market. Furthermore, some of the key trends going on in the market are the implementation of liquid biopsy for breast cancer diagnosis and the complete automation of next-generation techniques.

Impact of COVID-19

COVID-19 had a significant impact on the global next-generation breast cancer diagnostic and screening market. There was a significant shift observed toward research activities for treating and diagnosing COVID-19, which resulted in a halt in research activities for next-generation breast cancer diagnostic and screening. Moreover, the market players witnessed a loss in 2020 due to COVID-19 restrictions and prevention actions such as a reduction in supply chain and sales.

However, since the situations are now almost back to normal, the next-generation breast cancer diagnostic and screening market is expected to overcome all the impact of COVID-19 during the forecast period 2023-2032.

Market Segmentation:

Segmentation 1: by Technology

• Real-Time PCR
• Immunohistochemistry (IHC)
• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Others

Based on technology, the global next-generation breast cancer diagnostic and screening market is expected to be dominated by the immunohistochemistry (IHC) segment.

Segmentation 2: by Biomarker

• BRCA1/2
• ER/PR Receptors
• HER-2
• Others

Based on biomarker, the global next-generation breast cancer diagnostic and screening market is dominated by the BRCA1/2 segment.

Segmentation 3: by Cancer Sub-Type

• Luminal A
• Luminal B
• Triple Negative/Basal Like
• Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

Based on cancer sub-type, the global next-generation breast cancer diagnostic and screening market is dominated by the luminal A segment.

Segmentation 4: by Offering

• Products
• Services

Based on offering, the global next-generation breast cancer diagnostic and screening market is dominated by the services segment.

Segmentation 5: by End User

• Hospitals and Clinics
• Diagnostic Centers and Reference Labs
• Academic and Research Institutes

Based on end user, the global next-generation breast cancer diagnostic and screening market is dominated by the hospitals and clinics segment.

Segmentation 6: by Region

• North America - U.S., Canada

• Europe - Germany, France, U.K., Italy, Spain, and Rest-of-Europe

• Asia-Pacific - Japan, China, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

• Latin America - Brazil, Mexico, and Rest-of-Latin America

• Rest-of-the-World

Based on region, the global next-generation breast cancer diagnostic and screening market is dominated by North America.

Recent Developments in the Global Next-Generation Breast Cancer Diagnostic and Screening Market

• In April 2023, Syantra Inc., a Canada-based company, received CE mark approval for its Syantra DX breast cancer test.

• In March 2023, NeoGenomics, Inc. launched its RaDaR assay, which is a liquid biopsy test for minimal residual disease (MRD).

• In February 2023, HALO Diagnostics launched its new HALO pathway for early breast cancer detection.

• In January 2023, Agilent Technologies, Inc. acquired Avida Biomed, a company that develops high-performance NGS target enrichment workflows for cancer research.

• In October 2022, Lucence Diagnostics Pte Ltd entered into a distribution partnership with Omnigen, under which Omnigen would distribute Lucence Diagnostics Pte Ltd's LiquidHALLMARK assay in Turkey.

• In March 2022, Myriad Genetics, Inc. received the U.S. FDA approval for its BRACanalysis CDx for being used as a companion diagnostic test and for the identification of breast cancer patients who may benefit from Lynparza in early breast cancer stages.

• In February 2022, Laboratory Corporation of America Holdings acquired Personal Genome Diagnostics Inc., a company that deals in cancer genomics and provides an assortment of comprehensive liquid biopsy and tissue-based products.

• In January 2022, Agendia Inc. entered into a partnership with Illumina Inc. to expand genomic testing for breast cancer care.

• In December 2021, Exai Bio, Inc. raised funding of $67.5 million as a part of its Series A funding round. The funding was in order to bring advancement in the next-generation RNA-based liquid biopsy platform of the company, which is indicated for early detection of cancer.

• In June 2021, Veracyte, Inc. acquired HalioDx for an amount of $318 million to expand its portfolio in cancer in-vitro diagnostics.

• In May 2021, Hologic, Inc. acquired Biotheranostics, Inc., a company that provides molecular diagnostic tests for breast and metastatic cancers.

• In November 2020, Agilent Technologies, Inc. received U.S. FDA approval for its PD-L1 IHC 22C3 pharmDx for triple-negative breast cancer.

Demand - Drivers and Limitations

Following are the drivers for the global next-generation breast cancer diagnostic and screening market:

• Increasing Prevalence of Breast Cancer Globally
• Increased Awareness Regarding Early Diagnosis of Breast Cancer
• Growing Focus on Breast Cancer Biomarkers for Effective Screening, Prognosis, and Personalized Treatment
• Increasing Partnerships and Collaborations amongst Market Players

The market is expected to face some limitations as well due to the following restraints:

• High Cost of Tests and Requirement of High Capital Investment for Testing Set-Up
• Occurrence of False Positive and False Negative Results

How can this report add value to an organization?

• Product/Innovation Strategy: The technology segment helps the reader understand the different types of technologies being used in next-generation breast cancer diagnosis and screening. Moreover, the study provides the reader with a detailed understanding of the next-generation breast cancer diagnostic and screening market based on biomarkers (BRCA1/2, ER/PR receptors, HER-2, and others), cancer sub-type (luminal A, luminal B, triple negative/basal-like, and HER-2 enriched), and offerings (products and services).

• Growth/Marketing Strategy: The global next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the global next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.

• Competitive Strategy: Key players in the global next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, and market penetration.

Key Companies Profiled:

Table of Contents

1 Oncology Molecular Diagnostic Market

• 1.1 Overview
• 1.2 Cancer Type
• 1.3 Technology
• 1.4 Market Dynamics
• 1.5 Regulatory-Approved Products

2 Global Next-Generation Breast Cancer Diagnostic and Screening Market

• 2.1 Global Market Outlook
  • 2.1.1 Product Definition
  • 2.1.2 Definition by Technologies Involved
    • 2.1.2.1 Real-Time Polymerase Chain Reaction (RT-PCR)
    • 2.1.2.2 Fluorescence In-Situ Hybridization (FISH)
    • 2.1.2.3 Next-Generation Sequencing
    • 2.1.2.4 Immunohistochemistry (IHC)
  • 2.1.3 Inclusion and Exclusion
  • 2.1.4 Overview
    • 2.1.4.1 Global Market Size and Growth Potential, $Million, 2022-2032

3 Industry Outlook

• 3.1 Key Trends
  • 3.1.1 Liquid Biopsy for Breast Cancer Diagnosis
  • 3.1.2 Complete Automation of Next-Generation Techniques
• 3.2 Regulatory Framework
  • 3.2.1 Regulatory Framework in the U.S.
    • 3.2.1.1 FDA Regulation
    • 3.2.1.2 CMS Regulations (Reimbursement Scenario)
  • 3.2.2 Regulatory Framework in Europe
  • 3.2.3 Regulatory Framework in Asia-Pacific
    • 3.2.3.1 China
    • 3.2.3.2 Japan
• 3.3 Regulatory-Approved Products
• 3.4 Clinical Trials
• 3.5 Breast Cancer Incidence Growth Rates (by Country)
• 3.6 Advantages and Limitations of Different Techniques
• 3.7 Pricing

4 Impact of COVID-19 on Global Next-Generation Breast Cancer Diagnostic and Screening Market

• 4.1 Impact of COVID-19 on Next-Generation Breast Cancer Diagnostic and Screening Overall Market
• 4.2 Pre-COVID-19 Phase
• 4.3 During-COVID-19 Phase
• 4.4 Post-COVID-19 Phase

5 Business Dynamics

• 5.1 Impact Analysis
• 5.2 Business Drivers
  • 5.2.1 Increasing Prevalence of Breast Cancer Globally
  • 5.2.2 Increased Awareness Regarding Early Diagnosis of Breast Cancer
  • 5.2.3 Growing Focus on Breast Cancer Biomarkers for Effective Screening, Prognosis, and Personalized Treatment
  • 5.2.4 Increasing Partnerships and Collaborations amongst Market Players
• 5.3 Business Restraints
  • 5.3.1 High Cost of Tests and Requirement of High Capital Investment for Testing Set-Up
  • 5.3.2 Occurrence of False Positive and False Negative Results
• 5.4 Business Opportunities
  • 5.4.1 Technological Advancements in the Development of Next-Generation Breast Cancer Diagnostics
  • 5.4.2 Growing Scope for Molecular Breast Cancer Diagnosis Techniques in Emerging Countries

6 Competitive Landscape

• 6.1 Overview
• 6.2 Key Strategies and Developments
  • 6.2.1 Partnerships, Alliances, and Business Expansions
  • 6.2.2 Regulatory and Legal Activities
  • 6.2.3 Mergers and Acquisitions
  • 6.2.4 New Offerings
  • 6.2.5 Funding Activities
• 6.3 Market Share Analysis (by Company), 2022
• 6.4 Growth-Share Analysis (By Company), 2022

7 Global Next Generation Breast Cancer Diagnostic and Screening Market, By Technology

• 7.1 Overview
• 7.2 Growth-Share Matrix
• 7.3 Real-Time PCR (RT-PCR)
• 7.4 Immunohistochemistry (IHC)
• 7.5 Next-Generation Sequencing
• 7.6 Fluorescence In-Situ Hybridization (FISH)
• 7.7 Others

8 Global Next Generation Breast Cancer Diagnostic and Screening Market, by Biomarker

• 8.1 Overview
• 8.2 Growth-Share Matrix
• 8.3 BRCA1/2
• 8.4 ER/PR Receptors
• 8.5 Human Epidermal Growth Factor-2 (HER-2)
• 8.6 Others

9 Global Next Generation Breast Cancer Diagnostic and Screening Market, by Cancer Sub-Type

• 9.1 Overview
• 9.2 Growth-Share Matrix
• 9.3 Luminal A
• 9.4 Luminal B
• 9.5 Triple Negative/ Basal-Like
• 9.6 Human Epidermal Growth Factor-2 (HER-2) Enriched

10 Global Next Generation Breast Cancer Diagnostic and Screening Market, by Offering

• 10.1 Overview
• 10.2 Growth-Share Matrix
• 10.3 Products
• 10.4 Services

11 Global Next Generation Breast Cancer Diagnostics and Screening Market, by End User

• 11.1 Overview
• 11.2 Growth-Share Matrix
• 11.3 Hospitals and Clinics
• 11.4 Academic and Research Institutes
• 11.5 Diagnostic Centers and Reference Labs

12 Regions

• 12.1 North America
  • 12.1.1 Key Findings
  • 12.1.2 Market Dynamics
    • 12.1.2.1 Impact Analysis
  • 12.1.3 Market Sizing and Forecast
    • 12.1.3.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
      • 12.1.3.1.1 U.S.
        • 12.1.3.1.1.1 Market Dynamics
        • 12.1.3.1.1.2 Market Sizing and Forecast
      • 12.1.3.1.2 Canada
        • 12.1.3.1.2.1 Market Dynamics
        • 12.1.3.1.2.2 Market Sizing and Forecast
• 12.2 Europe
  • 12.2.1 Key Findings
  • 12.2.2 Market Dynamics
    • 12.2.2.1 Impact Analysis
  • 12.2.3 Market Sizing and Forecast
    • 12.2.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
      • 12.2.3.1.1 Germany
        • 12.2.3.1.1.1 Market Dynamics
        • 12.2.3.1.1.2 Market Sizing and Forecast
      • 12.2.3.1.2 France
        • 12.2.3.1.2.1 Market Dynamics
        • 12.2.3.1.2.2 Market Sizing and Forecast
      • 12.2.3.1.3 U.K.
        • 12.2.3.1.3.1 Market Dynamics
        • 12.2.3.1.3.2 Market Sizing and Forecast
      • 12.2.3.1.4 Italy
        • 12.2.3.1.4.1 Market Dynamics
        • 12.2.3.1.4.2 Market Sizing and Forecast
      • 12.2.3.1.5 Spain
        • 12.2.3.1.5.1 Market Dynamics
        • 12.2.3.1.5.2 Market Sizing and Forecast
      • 12.2.3.1.6 Rest-of-Europe
        • 12.2.3.1.6.1 Market Dynamics
        • 12.2.3.1.6.2 Market Sizing and Forecast
• 12.3 Asia-Pacific
  • 12.3.1 Key Findings
  • 12.3.2 Market Dynamics
    • 12.3.2.1 Impact Analysis
  • 12.3.3 Market Sizing and Forecast
    • 12.3.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
      • 12.3.3.1.1 China
        • 12.3.3.1.1.1 Market Dynamics
        • 12.3.3.1.1.2 Market Sizing and Forecast
      • 12.3.3.1.2 Japan
        • 12.3.3.1.2.1 Market Dynamics
        • 12.3.3.1.2.2 Market Sizing and Forecast
      • 12.3.3.1.3 India
        • 12.3.3.1.3.1 Market Dynamics
        • 12.3.3.1.3.2 Market Sizing and Forecast
      • 12.3.3.1.4 Australia
        • 12.3.3.1.4.1 Market Dynamics
        • 12.3.3.1.4.2 Market Sizing and Forecast
      • 12.3.3.1.5 South Korea
        • 12.3.3.1.5.1 Market Dynamics
        • 12.3.3.1.5.2 Market Sizing and Forecast
      • 12.3.3.1.6 Singapore
        • 12.3.3.1.6.1 Market Dynamics
        • 12.3.3.1.6.2 Market Sizing and Forecast
      • 12.3.3.1.7 Rest-of-Asia-Pacific
        • 12.3.3.1.7.1 Market Dynamics
        • 12.3.3.1.7.2 Market Sizing and Forecast
• 12.4 Latin America
  • 12.4.1 Key Findings
  • 12.4.2 Market Dynamics
    • 12.4.2.1 Impact Analysis
  • 12.4.3 Market Sizing and Forecast
    • 12.4.3.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
      • 12.4.3.1.1 Mexico
        • 12.4.3.1.1.1 Market Dynamics
        • 12.4.3.1.1.2 Market Sizing and Forecast
      • 12.4.3.1.2 Brazil
        • 12.4.3.1.2.1 Market Dynamics
        • 12.4.3.1.2.2 Market Sizing and Forecast
      • 12.4.3.1.3 Rest-of-Latin America
        • 12.4.3.1.3.1 Market Dynamics
        • 12.4.3.1.3.2 Market Sizing and Forecast
• 12.5 Rest-of-the-World
  • 12.5.1 Key Findings
  • 12.5.2 Market Dynamics
    • 12.5.2.1 Impact Analysis
  • 12.5.3 Market Sizing and Forecast

13 Markets - Competitive Benchmarking

• 13.1 Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
• 13.2 Company Profiles
  • 13.2.1 Abbott Laboratories
    • 13.2.1.1 Company Overview
    • 13.2.1.2 Role of Abbott Laboratories in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.1.3 Financials
    • 13.2.1.4 Analyst Perception
  • 13.2.2 Agendia Inc.
    • 13.2.2.1 Company Overview
    • 13.2.2.2 Role of Agendia Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.2.3 Recent Developments
    • 13.2.2.4 Analyst Perception
  • 13.2.3 Agilent Technologies, Inc.
    • 13.2.3.1 Company Overview
    • 13.2.3.2 Role of Agilent Technologies, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.3.3 Financials
    • 13.2.3.4 Recent Developments
    • 13.2.3.5 Analyst Perception
  • 13.2.4 Bio-Rad Laboratories, Inc.
    • 13.2.4.1 Company Overview
    • 13.2.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.4.3 Financials
    • 13.2.4.4 Analyst Perception
  • 13.2.5 BGI Genomics Co., Ltd.
    • 13.2.5.1 Company Overview
    • 13.2.5.2 Role of BGI Genomics Co., Ltd. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.5.3 Financials
    • 13.2.5.4 Recent Developments
    • 13.2.5.5 Analyst Perception
  • 13.2.6 CENTOGENE N.V.
    • 13.2.6.1 Company Overview
    • 13.2.6.2 Role of CENTOGENE N.V. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.6.3 Financials
    • 13.2.6.4 Recent Developments
    • 13.2.6.5 Analyst Perception
  • 13.2.7 Danaher Corporation
    • 13.2.7.1 Company Overview
    • 13.2.7.2 Role of Danaher Corporation in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.7.3 Financials
    • 13.2.7.4 Analyst Perception
  • 13.2.8 Exact Sciences Corporation
    • 13.2.8.1 Company Overview
    • 13.2.8.2 Role of Exact Sciences Corporation in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.8.3 Financials
    • 13.2.8.4 Recent Developments
    • 13.2.8.5 Analyst Perception
  • 13.2.9 F. Hoffmann-La Roche Ltd.
    • 13.2.9.1 Company Overview
    • 13.2.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.9.3 Financials
    • 13.2.9.4 Recent Developments
    • 13.2.9.5 Analyst Perception
  • 13.2.10 Illumina, Inc.
    • 13.2.10.1 Company Overview
    • 13.2.10.2 Role of Illumina, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.10.3 Financials
    • 13.2.10.4 Recent Developments
    • 13.2.10.5 Analyst Perception
  • 13.2.11 Laboratory Corporation of America Holdings
    • 13.2.11.1 Company Overview
    • 13.2.11.2 Role of Laboratory Corporation of America Holdings in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.11.3 Financials
    • 13.2.11.4 Recent Developments
    • 13.2.11.5 Analyst Perception
  • 13.2.12 Thermo Fisher Scientific Inc.
    • 13.2.12.1 Company Overview
    • 13.2.12.2 Role of Thermo Fisher Scientific Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.12.3 Financials
    • 13.2.12.4 Recent Developments
    • 13.2.12.5 Analyst Perception
  • 13.2.13 Lucence Diagnostics Pte Ltd
    • 13.2.13.1 Company Overview
    • 13.2.13.2 Role of Lucence Diagnostics Pte Ltd in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.13.3 Recent Developments
    • 13.2.13.4 Analyst Perception
  • 13.2.14 Myriad Genetics, Inc.
    • 13.2.14.1 Company Overview
    • 13.2.14.2 Role of Myriad Genetics, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.14.3 Financials
    • 13.2.14.4 Recent Developments
    • 13.2.14.5 Analyst Perception
  • 13.2.15 Natera, Inc.
    • 13.2.15.1 Company Overview
    • 13.2.15.2 Role of Natera, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
    • 13.2.15.3 Financials
    • 13.2.15.4 Recent Developments
    • 13.2.15.5 Analyst Perception